Jefferies Group LLC reiterated their hold rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. Jefferies Group LLC currently has a $93.00 price target on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Gilead Sciences’ Q3 2017 earnings at $1.86 EPS, Q4 2017 earnings at $1.66 EPS, FY2017 earnings at $8.21 EPS, Q1 2018 earnings at $1.58 EPS, Q2 2018 earnings at $1.54 EPS, Q3 2018 earnings at $1.49 EPS, Q4 2018 earnings at $1.52 EPS and FY2018 earnings at $6.15 EPS.

A number of other equities analysts have also recently weighed in on the stock. Argus upgraded shares of Gilead Sciences from a hold rating to a buy rating and set a $100.00 price objective for the company in a research report on Thursday, August 31st. Deutsche Bank AG restated a buy rating and set a $81.00 price objective on shares of Gilead Sciences in a research report on Thursday, August 31st. Credit Suisse Group restated an outperform rating and set a $85.00 price objective (up from $79.00) on shares of Gilead Sciences in a research report on Tuesday, August 29th. BidaskClub upgraded shares of Gilead Sciences from a strong sell rating to a sell rating in a research report on Thursday, June 22nd. Finally, Vetr upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $83.66 price objective for the company in a research report on Monday, June 26th. Twelve investment analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $85.66.

Gilead Sciences (GILD) opened at 82.14 on Wednesday. The stock has a market capitalization of $107.27 billion, a PE ratio of 8.92 and a beta of 1.14. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $86.27. The company’s 50-day moving average is $80.97 and its 200 day moving average is $71.66.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue for the quarter was down 8.2% on a year-over-year basis. During the same period in the prior year, the business posted $3.08 earnings per share. Equities analysts predict that Gilead Sciences will post $8.75 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/08/jefferies-group-llc-reiterates-hold-rating-for-gilead-sciences-inc-gild.html.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.53%. Gilead Sciences’s dividend payout ratio is presently 22.58%.

In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the sale, the executive vice president now owns 106,113 shares of the company’s stock, valued at $8,051,854.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total transaction of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at approximately $10,174,112. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock worth $39,298,919 in the last three months. Corporate insiders own 1.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Keel Point LLC lifted its position in shares of Gilead Sciences by 0.4% during the first quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 11 shares in the last quarter. Paradigm Financial Advisors LLC lifted its position in shares of Gilead Sciences by 0.3% during the second quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after purchasing an additional 26 shares in the last quarter. West Oak Capital LLC lifted its position in shares of Gilead Sciences by 0.7% during the second quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 32 shares in the last quarter. First Heartland Consultants Inc. lifted its position in shares of Gilead Sciences by 0.4% during the second quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after purchasing an additional 39 shares in the last quarter. Finally, Princeton Portfolio Strategies Group LLC lifted its position in shares of Gilead Sciences by 0.4% during the second quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 41 shares in the last quarter. 73.99% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.